Berberine Inhibits Gluconeogenesis in Skeletal Muscles and Adipose Tissues in Streptozotocin-induced Diabetic Rats via LKB1-AMPK-TORC2 Signaling Pathway

Abstract

The effect and potential molecular mechanisms of berberine on gluconeogenesis in skeletal muscles and adipose tissues were investigated. After adaptive feeding for one week, 8 rats were randomly selected as the normal group and fed on a standard diet. The remaining 32 rats were fed on a high-fat diet and given an intravenous injection of streptozotocin (STZ) for 2 weeks to induce the diabetic models. The diabetic rat models were confirmed by oral glucose tolerance test (OGTT) and randomly divided into 4 groups (n=8 each), which were all fed on a high-fat diet. Berberine (3 g/kg per day) or metformin (183 mg/kg per day) was intragastrically administered to the diabetic rats for 12 weeks, serving as berberine group and metformin group respectively. 5-aminoimidazole-4-carboxamide1-β-D-ribofuranoside [AICAR, an agonist of AMP-activated protein kinase (AMPK), 0.5 mg/kg per day] was subcutaneously injected to the diabetic rats for 12 weeks, serving as AICAR group. The remaining 8 diabetic rats served as the model group, which was given a 0.5% carboxyl methylcellulose solution by oral gavage. Fasting serum insulin (FINS), OGTT as well as lipid parameters were tested by commercial kit. The protein levels of liver kinase B1 (LKB1), AMPK, phosphorylated AMP-activated protein kinase (p-AMPK), transducer of regulated CREB activity 2 (TORC2), phosphorylated transducer of regulated CREB activity 2 (p-TORC2), phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) in skeletal muscles and adipose tissues were examined by Western blotting. The results showed that berberine significantly decreased the body weight, plasma glucose, insulin levels, and homeostatic model assessment for insulin resistance (HOMA-IR) of diabetic rats compared with those in the model group. Meanwhile, the serum total triglyceride (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels were markedly decreased and high-density lipoprotein cholesterol (HDL-C) level was significantly increased after the treatment with berberine. In addition, we found that berberine significantly increased the expression of p-AMPK and LKB1, while decreasing the p-TORC2 levels in skeletal muscles and adipose tissues. Moreover, the expression of PEPCK and G6Pase was significantly down-regulated after the treatment with berberine compared to the model group. It was suggested that the mechanism by which berberine inhibited peripheral tissue gluconeogenesis may be attributed to the activation of the LKB1-AMPK-TORC2 signaling pathway.

Keywords

berberine / gluconeogenesis / skeletal muscle / adipose tissue / LKB1-AMPK-TORC2

References

[1] RowleyWR, BezoldC, ArikanY, et al.. Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag, 2017, 20(1): 6-12

[2] HuF. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care, 2011, 34(6): 1249-1257

[3] GastaldelliA. Role of beta-cell dysfunction, ectopic fat accumulation and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Diabetes Res Clin Pract, 2011, 93: S60-S65

[4] LiuXT, LiYQ, LiLL, et al.. Prevalence, awareness, treatment, control of type 2 diabetes mellitus and risk factors in Chinese rural population: the RuralDiab study. Sci Rep, 2016, 6: 31426

[5] TanMH, AlqurainiH, Mizokami-StoutK, et al.. Metformin: From Research to Clinical Practice. Endocrinol Metab Clin North Am, 2016, 45(4): 819-843

[6] RiosJL, FranciniF, SchinellaGR. Natural Products for the Treatment of Type 2 Diabetes Mellitus. Planta Med, 2015, 81(12–13): 975-994

[7] SunY, XiongYY, WuHZ, et al.. Active Ingredients and Mechanism of Action of Rhizoma Coptidis against Type 2 Diabetes Based on Network-Pharmacology and Bioinformatics. Curr Med Sci, 2020, 40(2): 257-264

[8] WangH, ZhuC, YingY, et al.. Metformin and berberine, two versatile drugs in treatment of common metabolic diseases. Oncotarget, 2018, 9(11): 10 135-10 146

[9] YanM, QiH, XiaT, et al.. Metabolomics profiling of metformin-mediated metabolic reprogramming bypassing AMPKa. Metabolism, 2018, 91: 18-29

[10] ShenN, HuanY, ShenZF. Berberine inhibits mouse insulin gene promoter through activation of AMP activated protein kinase and may exert beneficial effect on pancreatic β-cell. Eur J Pharmacol, 2012, 694(1–3): 120-126

[11] KimWS, LeeYS, ChaSH, et al.. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab, 2009, 296: E812-E819

[12] JiangSJ, DongH, LiJB, et al.. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol, 2015, 21(25): 7777-7785

[13] ChenG, LuFE, JinD, et al.. Effect of Huanglian Jiedu decoction on glucose transporter 4 expression in adipose and skeletal muscle tissues of insulin resistant rats. Chin J Integr Med, 2007, 13(1): 41-45

[14] DefronzoRA, JacotE, JequierE, et al.. The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes, 1981, 30(12): 1000-1007

[15] WinderWW, HardieDG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol, 1999, 277: E1-E10

[16] MiyakiA, ChoiY, MaedaS. Pentraxin 3 production in the adipose tissue and the skeletal muscle in diabetic-obese mice. Am J Med Sci, 2014, 347(3): 228-233

[17] GolayA, YbarraJ. Link between obesity and type 2 diabetes. Best Pract Res Clin Endocrinol Metab, 2005, 19(4): 649-663

[18] ZhangCY, BaffyG, PerretP, et al.. Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell, 2001, 105(6): 745-755

[19] MillerR A, ChuQ, Le LayJ, et al.. Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J Clin Invest, 2011, 121(6): 2518-2528

[20] PetersenMC, VatnerDF, ShulmanGL. Regulation of hepatic glucose metabolism in health and disease. Nat Rev Endocrinol, 2017, 13(10): 572-587

[21] CoughlanKA, ValentineRJ, RudermanNB, et al.. AMPK activation: a therapeutic target for type 2 diabetes?. Diabetes Metab Syndr Obes, 2014, 7: 241-253

[22] WangY, VeraL, FischerWH, et al.. The CREB coactivator CRTC2 links hepatic ER stress and fasting gluconeogenesis. Nature, 2009, 460(7254): 534-537

[23] DentinR, LiuY, KooSH, et al.. Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature, 2007, 449(7160): 366-369

[24] Dong H, Wang N, Zhao L, et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med, 2012,591654

[25] XiaX, YanJH, ShenYF, et al.. Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis. PLoS One, 2011, 6: e16556

[26] HanX, TaoYL, DengYP, et al.. Metformin ameliorates insulitis in STZ-induced diabetic mice. PeerJ, 2017, 5: e3155

[27] ShawRJ, LamiaKA, VasquezD, et al.. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 2005, 310(5754): 1642-1646

[28] RourkeJL, HuQ, ScreatonRA. AMPK and Friends: Central Regulators of β Cell Biology. Trends Endocrinol Metab, 2018, 29(2): 111-122

[29] ZhangYP, DengYJ, TangKR, et al.. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. Curr Med Sci, 2019, 39(1): 37-43

[30] CanettieriG, KooS H, BerdeauxR, et al.. Dual role of the coactivator TORC2 in modulating hepatic glucose output and insulin signaling. Cell Metab, 2005, 2(5): 331-338

[31] KumarA, HarrisTE, KellerSR, et al.. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol, 2008, 28(1): 61-70

[32] KooSH, FlechnerL, QiL, et al.. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 2005, 437(7062): 1109-1111

[33] ScreatonRA, ConkrightMD, KatohY, et al.. The CREB coactivator TORC2 functions as a calcium- and cAMPsensitive coincidence detector. Cell, 2004, 119(1): 61-74

[34] Zhang WY, Zhang XL, Wang H, et al. AMP-activated protein kinase alpha1 protects against diet-induced insulin resistance and obesity. Diabetes, 2012,61,3114–3125